|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mixed polyanion cathode materials:Toward stable and high-energy sodium-ion batteries显示文摘Sodium-ion batteries(SIBs)are considered as one of the most fascinating alternatives to lithium-ion batteries for grid-scale energy storage applications because of the low cost and wide abundance of sodium resources.Among various cathode materials,mixed polyanion compounds come into the spotlight as promising electrode materials due to their superior electrochemical properties,such as high working voltage,long cycling stability,and facile reaction kinetics.In this review,we summarize the recent development in the exploration of different mixed polyanion cathode materials for SIBs.We provide a comprehensive understanding of the structure-composition-performance relationship of mixed polyanion cathode materials together with the discussion of their sodium storage mechanisms.It is anticipated that further innovative works on the material design of advanced cathode materials for batteries can be inspired. | Along Zhao Yongjin Fang Xinping Ai Hanxi Yang Yuliang Cao | 2021 | Journal of Energy Chemistry2021，30，9： | 4 |
| 2 | Clinical characteristics and outcomes of Chinese patients with KRAS-mutant non-small cell lung cancer after chemotherapy显示文摘Dear Editor,The RAS gene is one of the most frequent oncogenes in human cancers,with significantly different mutation frequencies.The RAS family contains three isoforms:KRAS,HRAS and NRAS,with the KRAS mutations being more common than the other two.The KRAS mutation rate varies in non-small cell lung cancer(NSCLC)patients of different races:27%in Caucasians[1]and approximately 10%in Asians[2,3].Recently,the U.S.Food and Drug Administration(FDA)approved sotorasib(AMG510)and adagrasib(MRTX849)for the treatment of metastatic NSCLC harboring KRAS G12C mutations.In the face of novel treatment choices for KRAS-mutated NSCLC,it is indispensable to learn more about the systemic treatment of these patients.Clinical studies have shown that Caucasian patients with KRAS-mutated NSCLC had poor outcomes following first-line chemotherapy[4,5].However,studies on treatment outcomes of Asian patients with KRAS-mutated NSCLC are lacking.As the overwhelming majority of cases are diagnosed with lung adenocarcinoma,the standard first-line treatment for metastatic disease is pemetrexed-based doublet chemotherapy in combination with bevacizumab and/or immunotherapy in China.Herein,we investigated the clinical characteristics of KRAS mutation subtypes,co-occurring genomic alterations,and efficacy of first-line pemetrexed-platinum chemotherapy in Chinese KRAS-mutated NSCLC patients. | Yawen Zheng Qinghua Lai Hanxi Zhao Xiaolin Li Xiaorong Sun Ligang Xing | 2021 | Cancer Communications2021，41，11： | 4 |
| 3 | Efficacy of oral epigallocatechin-3-gallate solution administration during radiotherapy for non-small-cell lung cancer patients: A long-term observational study显示文摘Objective:Several studies have found that epigallocatechin-3-gallate(EGCG)can alleviate acute radiation-induced esophagitis,inhibit pulmonary inflammation and fibrosis,and reduce the severity of cardiovascular disease.Therefore,this study was aimed at exploring the influence of EGCG on late radiation toxicity in the heart,esophagus,and lungs among patients with locally advanced lung cancer.Methods:The patients were divided into an EGCG group and a control group,the groups received EGCG and symptomatic treatment,respectively.The Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer Late Radiation Morbidity Scoring Scheme was used to determine the late toxicity scores.Tumor responses were evaluated by chest computed tomography(CT),based on the Response Evaluation Criteria in Solid Tumors version 1.1.Results:We retrospectively analyzed 74 patients treated at our hospital from September 2012 to September 2016(37 patients received EGCG and 37 received supportive treatment).The late toxicity scores of the EGCG group decreased compared to those of the control group.An obvious clinical significance was observed for the oral EGCG solution in the treatment and prevention of late cardiac,esophageal,and pulmonary toxicity.However,no significant difference was found(P>0.05).The tumor response rates were similar in the two groups.Moreover,there was no difference in progression-free survival(PFS)between the groups(P>0.05).Conclusion:Oral EGCG solution might alleviate radiation-induced late cardiac,esophageal,and pulmonary toxicity but has no significant effect on the tumor response rate and PFS following radiotherapy. | Xuena Niu Hanxi Zhao Wanqi Zhu Yahui Zhao Xiaolan Cao Ligang Xing | 2020 | Radiation Medicine and Protection2020，1，2： | 0 |
| 4 | Variation and stability analysis of growth traits of poplar clones in the seedling stage in northeast China显示文摘Plant phenotypes are infl uenced by genetic and environmental factors.In this study,the growth traits of 43 one-year-old poplar clones grown at diff erent sites in northeast China(Dongling State-owned Forest Protection Center,DL;Baicheng State-owned forest farm,BC;and Cuohai Forest farm,CH)were evaluated and analyzed across clones and sites.Results show signifi cant diff erences in height and base diameter among sites and clones.Phenotypic and genetic variation coeffi cients ranged from 49.59%(BC)to 58.39%(DL)and from 49.33%(BC)to 58.06%(DL),respectively.Additive main eff ects and multiplicative interaction(AMMI)analysis showed that the eff ects of genotype,environment,and genotype×environment interaction were signifi cantly diff erent.Genetic variation was the main source of variation,accounting for 48.6%.AMMI biplot showed that clone 30 had high and stable yields at the three sites.From an evaluation of multiple traits and GGE biplot that clone 2,clone 30 and clone 25 had higher yield than the other clones at DL,CH and BC,respectively.These clones will provide material for forest regeneration in northeast China. | Xiaoting Liu Qiushuang Zhao Peng Yin Hanxi Li Xuesong Li Liguo Wu Yueji Li Yanbo Hu Xiyang Zhao | 2023 | Journal of Forestry Research2023，34，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员